All In MedTech

Device Trial Radar · NCT07356505

Efficacy and Safety of Micra AV2 Transcatheter Pacing System

Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 12, 2026

Primary completion

Jun 30, 2027

Study completion Jan 31, 2029

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic
First posted
Jan 21, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A third generation, Micra AV2 is now available and proposes increased automaticity and improved AV synchrony algorithms based on computing model. The new algorithms permit the delivery of AV synchronous pacing, improving the automatic AV synchrony at faster heart rates between 80-100 bpm with a maximal upper tracking rate limit of 135 bpm (previously 115-120 bpm in the Micra AV1). Micra AV2 presents also a potential extended longevity of 15.6 years (increased by \> 44% in comparison of Micra AV1). Up to now, no clinical study has evaluated the efficacy and safety of Micra AV2 in a real-world setting. The focus of this study is to characterize chronic ambulatory AV synchrony in patients with high degree AV block and normal sinus rhythm implanted with a Micra AV2 as primary objective to evaluate AV synchrony during exercise as secondary objective.

Conditions

  • AV Block Complete
  • AV Block-2Nd Degree-Type 1
  • AV Block

Interventions

  • Implant procedure of a Micra AV2 leadless pacemaker (Medtronic)Device

    All patients will be implanted with aMicra AV2 leadless pacemaker

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AV synchrony at 6 monthsTime frame: 6 months follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospitals of Leuven

    Leuven, Flemish Brabant, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.